Arcus Biosciences (RCUS) Operating Income (2017 - 2026)

Arcus Biosciences' Operating Income history runs 10 years deep, the most recent figure standing at -$134.0 million for Q1 2026.

• On a quarterly basis, Operating Income fell 9.84% year-over-year to -$134.0 million in Q1 2026; TTM through Mar 2026 was -$398.0 million, a 8.72% increase from a year earlier, with the FY2025 full-year figure at -$386.0 million, down 16.97% from the prior year.
• Operating Income eased to -$134.0 million in Q1 2026 per RCUS's latest filing, from -$114.0 million in the prior quarter.
• Across five years, Operating Income topped out at -$8.0 million in Q2 2025 and bottomed at -$142.0 million in Q3 2025.
• The 5-year median for Operating Income is -$86.0 million (2023), against an average of -$86.5 million.
• Biggest YoY gain for Operating Income was 92.45% in 2025; the steepest drop was 662.5% in 2025.
• Year by year, Operating Income stood at -$74.0 million in 2022, then slipped by 22.97% to -$91.0 million in 2023, then dropped by 13.19% to -$103.0 million in 2024, then declined by 10.68% to -$114.0 million in 2025, then slipped by 17.54% to -$134.0 million in 2026.
• Per Business Quant, the three latest RCUS Operating Income figures stand at -$134.0 million (Q1 2026), -$114.0 million (Q4 2025), and -$142.0 million (Q3 2025).